Study Finds 17% Of Patients With Rheumatologic Diseases Are Cannabis Consumers
In a new study, almost 20% of patients with rheumatologic illnesses use cannabis to relieve their symptoms.
November 20, 2020
A study by a team of researchers in France has found that 17% of patients with rheumatologic diseases consume cannabis. A report on the study, “Cannabis use assessment and its impact on pain in rheumatologic diseases: A systematic review and meta-analysis,” was posted online this month prior to its publication in the journal Rheumatology.
To conduct the study, researchers in Clermont-Ferrand, France, performed a systematic review of scientific literature published through June 2020 on the use of cannabis to treat rheumatologic diseases. Rheumatologic diseases include conditions such as fibromyalgia (FM), lupus, and rheumatoid arthritis.
The studies reviewed covered a total of 10,873 patients, including 2,900 who said that they consumed cannabis. The incidence of cannabis use was then calculated by meta-proportion.
“Nearly 20% of patients suffering from rheumatologic diseases actively consume cannabis, with an improvement in pain,” the authors of the study concluded.
Patients Often Self-Medicate With Cannabis